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ABSTRACT 
 Large-scale genomics projects such as the Cancer Genome Atlas (TCGA), and the 
Encyclopedia of DNA Elements (ENCODE) involve generation of data at an 
unprecedented scale, requiring new computational techniques for analysis and 
interpretation. In the three studies I present in this thesis, I utilize these data sources to 
derive biological insights or created visualization tools that enable others to obtain 
insights more easily. First, I examine the distribution of the lengths for copy number 
variations (CNVs) in the cancer genome. This analysis shows that a small number of 
genes are altered at a greater frequency than expected from a power law distribution, 
suggesting that a large number of genomes must be sequenced for a given tumor type to a 
comprehensive discovery of somatic mutations. Second, I investigate germline CNVs in 
thousands of TCGA samples using single nucleotide polymorphism (SNP) array data to 
find variants that may confer increased susceptibility to cancer. This CNV-based 
	  	   iv 
genome-wide association study resulted in many germline CNVs that potentially increase 
risk in brain, breast, colorectal, renal, or ovarian cancers. Finally, I apply several 
visualization techniques to create tools for the TCGA and ENCODE projects in order to 
help investigators better process and synthesize meaning from large volume of data. 
Seqeyes combines linear and circular genomic views to explore predicted structural 
variations to help guide experimental validation. The modEncode browser visualizes 
chromatin organization by integrating data from a multitude of histone marks and 
chromosomal proteins. These results present visualization as a useful strategy for rapid 
identification of salient genomic features from large, heterogeneous genomic datasets.  
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1 Introduction 
“From the dawn of civilization until 2003, humankind generated 5 exabytes of data. Now we produce 5 
exabytes every 2 days… and the pace is accelerating.”  - Eric Schmidt, Google 
Large-scale genomic projects designed to identify molecular mechanisms underlying 
human diseases are generating unprecedented amounts of data and a corresponding 
surge in sophisticated algorithms for detecting genomic aberrations and epigenetic 
modifications that cause disease. 
Data has been referred to as the ‘new oil’ with biology as a prime example of ‘big 
data,’ which refers to data sets whose size are beyond the ability for common software 
tools to analyze, manage, and visualize within a reasonable time frame. Big data 
bioinformatics projects such as the Cancer Genome Atlas (TCGA), and the Encyclopedia 
of DNA Elements (ENCODE) involve generation and interpretation of data at an 
unprecedented scale requiring new computational techniques for meaningful analysis. 
The goal of bioinformatics is to increase biological insights by developing and applying 
computational and statistical techniques and tools. There is great need to automate and 
apply analytical approaches to provide investigators the proper insights to make new and 
significant discoveries. Personalized medicine struggles with how to effectively leverage 
massive amounts of data to identify oncogenic variants that enable early detection or 
more effective patient-centric therapies.  
My contributions include method development: 1) to understand the distributions 
of large-scale copy number cancer data; 2) to identify novel germline copy number 
variations that confer increased risk in brain, breast, colorectal, renal, and ovarian 
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cancers across thousands of individuals; 3) to apply visualization techniques that enable 
investigators to better understand the nature of structural variation in cancer and the 
structure of chromatin with the data available from the high throughput experimental 
technologies. These studies present useful strategies for identifying and characterizing 
disease-associated variants and visualization techniques for exploring the variety and 
volume of data from large-scale sequencing studies. In the remainder of this chapter, I 
review the main technologies and datasets used in the following chapters. 
 
1.1 Review of Large-Scale Sequencing Studies  
Advances in next generation sequencing (NGS) machines produce terabytes of 
data and are enabling analysis of hundreds to thousands of patients. Public data 
repositories such as the NCBI’s Gene Expression Omnibus (GEO) and Sequence Read 
Archive (SRA) host data for thousands of published experiments (Edgar, 2002; Wheeler et 
al., 2000). The data has become so massive that few researchers have the tools and 
computing power to locate, integrate, and access them. The problem is so severe that the 
government has launched a Big Data Initiative providing 200 million dollars in funding to 
six government agencies including the NSF and NCI to the advancement of tools and 
methods for merging, analyzing, visualizing, and extracting insights from large datasets. 
The following are several of the active large-scale sequencing projects that produced data 
that we helped interpret and analyze in the following chapters. 
 
1.1.1. The Cancer Genome Atlas 
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The Cancer Genome Atlas (TCGA) (Cancer Genome Atlas Network, 2008, 2011, 
2012a, 2012b) is a comprehensive effort to accelerate the understanding of the molecular 
basis of cancer through the application of genome analysis technologies including large-
scale genome sequencing for at least 500 tumors for over 20 major types and subtypes of 
cancer. Genome-wide technologies used include gene expression profiling, copy number 
variation profiling, SNP genotyping, methylation profiling, microRNA profiling, exon 
sequencing, and whole genome sequencing (WGS). Data from thousands of tumors can 
amount to over 400 GB per patient. Since 2008, approximately 5 petabytes of data have 
accumulated as the TCGA has adapted to the rapid advancement of sequencing 
technology.  
 
1.1.2. Encyclopedia of DNA Elements 
Encyclopedia of DNA Elements (ENCODE) Consortium is an international 
collaboration building a comprehensive parts list of functional elements in the genome 
(Dunham et al., 2012). Over 1600 experiments on ~180 cell types were conducted to 
generate data spread across 12,000 files generating over 15 TB of experimental data 
systematically mapping regions of transcription, transcription factor association, 
chromatin structure and histone modification. The ENCODE project has assigned 
biochemical associations with putative function for up to 80% of the human genome 
including many genomic areas without previously known functions such as genes, 
promoters, enhancers, repressors/silencers, exons, origins of replication, sites of 
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replication termination, transcription factor binding sites, methylation sites, 
deoxyribonuclease I (DNase I) hypersensitive sites, and chromatin modifications. 
 
1.1.3. 1000 Genomes Project  
1000 Genomes Project began in 2008 to build the most detailed map of human 
genetic variation with genomes of over 2,600 people for any genetic variant that occurs 
more than 1% in any of the 26 populations studied with over 200 TB of data available 
(Abecasis et al., 2010). 
 
Analysis of massive and heterogeneous datasets from these large-scale studies 
poses several challenges, including effective data visualization, seamless connection of 
low-level (close to raw data) and high-level (close to answering biological questions) 
analysis, integration of data from multiple technological platforms, and flexibility to 
customize the analysis so that specific biological questions can be addressed. The Data 
and Informatics Working Group to the NIH Director stated, "Colossal changes in 
biomedical research technologies and methods have shifted the bottleneck in scientific 
productivity from data production to data management, communication, and 
interpretation. 
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2 Power Law Distribution of the Population Frequency of Chromosomal 
Alterations in Human Cancer Genomes 
Genomic dosage changes (chromosomal copy number gains and losses) represent one of 
the major categories among the frequent genomic alterations in human cancer genomes.  
In this study, we investigated the relationship between the population and gene-level 
frequencies of copy number changes in ~400 glioblastoma multiforme (GBM) tumors of 
the Cancer Genome Atlas.  We observed that the population frequency of high copy 
changes (multi-copy amplifications and homozygous deletions) as well as concordant copy 
number follow a power law distribution.  This indicates that a small number of genes are 
more frequently altered than expected while the majority of the observed alterations are 
observed in a few samples.  Although the recurrent genomic alterations and their 
involving genes have been considered as potential candidates of ‘fit-to-all-sizes’ 
biomarkers, our results suggest that the non-recurrent alterations constitute the major 
fraction of genomic signatures of cancer cells.  To explore the functional significance, we 
constructed functional module map using Gene Ontology (GO) functional annotations.  
We show that the functional changes in the most frequently amplified and deleted genes, 
as well as pathways identified by Gene Set Enrichment Analysis (GSEA), recapitulate 
genes and pathways already implicated in GBM.  
 
2.1 Introduction 
Various types of genomic alterations constitute the genetic ‘makeup’ of cancer 
genomes (Albertson, Collins, McCormick, & Gray, 2003; Greenman et al., 2007).  Such 
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genomic changes can occur in a scale as small as nucleotide-level (somatic point 
mutations and small indels) to chromosome-wide level (chromosomal 
amplifications/deletions and interchromosomal translocations).  Some of the genomic 
alterations in cancer genomes can contribute to tumorigenesis by affecting the activity of 
critical cancer genes (e.g., oncogenes and tumor suppressor genes), but such ‘driver’ 
alterations comprise a small fraction compared to ‘passenger’ alterations that are 
incidentally fixed during cancer clonal evolution without apparent survival or growth 
benefits (Hanahan & Weinberg, 2011).  One of the key challenges in cancer genomics is 
how to discriminate such ‘driver’ alterations from mere ‘passenger’ alterations. 
Traditionally, it has been assumed that recurrent genomic alterations are more 
likely to be ‘driver’ given an intuition that mutations in genes observed more often across 
a set of tumors are more likely to have resulted from an evolutionary selection process 
and represent mutations essential for tumorigenesis (Torkamani, Verkhivker, & Schork, 
2009). Accordingly, the algorithms to identify recurrent somatic mutations such as 
MutSig (Lawrence et al., 2013) or copy number alterations including GISTIC 
(Beroukhim et al., 2007) are based on identifying significantly recurrent alterations in 
multiple samples above the expected or background alteration rates. These analyses 
highlight the recurrent alterations as potential driver alterations assuming the non-
recurrent alterations are likely to be passenger events that do not contribute to 
oncogenesis.  Although it is generally believed that a majority of somatic alterations are 
likely to be passengers, it is possible that many of the changes may still possess functional 
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significance as genomic aberrations occurring less than 1% of tumors can behave as 
drivers (H. Carter et al., 2009).  
A number of studies, mainly using low-resolution cytogenetic data and small 
sample sizes, have analyzed the distribution of population frequency or sample-level 
frequency of large scale chromosomal alterations across diverse tumor types (Frigyesi, 
Gisselsson, Mitelman, & Höglund, 2003). In this study, we used copy number profiles of 
378 glioblastoma multiforme (GBM) from the Cancer Genome Atlas (TCGA) consortium. 
We observed that the number of chromosomal alterations per tumor follows a power-law 
distribution indicating that there are a small number of samples showing a large number 
of alterations, but the majority of samples show a few number of alterations resulting in 
long-tail distribution. The power law distribution was also observed in the distribution of 
population frequency (the number of samples showing the corresponding aberrations) at 
the cytoband level, i.e., a small number of cytobands show frequent chromosomal 
breakpoints with a majority of cytobands showing less frequent breakpoints. Power law 
distributions occur over a range of natural and man-made phenomena as well as various 
biological and social networks (Barabási & Oltvai, 2004; Clauset, Shalizi, & Newman, 
2009);  however, this is the first report for cancer genome configuration in terms of 
frequency of chromosomal alterations.  
 
2.2 Methods and Data 
We downloaded copy number profiles of 378 GBM genotyped on the Affymetrix 
SNP 6.0 platform from the Cancer Genome Atlas Data Portal (https://tcga-
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data.nci.nih.gov). CEL files were downloaded as pairs (tumor and matched normal) for 
each of the GBM cases. We processed and normalized the signals using Copy-number 
estimation using Robust Multichip Analysis (CRMAv2) (Bengtsson, Wirapati, & Speed, 
2009) and calculated log2 ratio (tumor/matched normal) for each of the probes. 
Segmentation of normalized log2 ratios were performed using Circular Binary 
Segmentation (CBS) algorithm with default settings (Olshen, Venkatraman, Lucito, & 
Wigler, 2004).   
For a defined cutoff of amplification and deletions, we counted the number of 
genes that belong to any of the segments whose log2 ratios are above or below the cutoffs.   
The observed distribution was compared with those from permutation tests and Poisson 
distribution. Permutation was performed by shuffling the gene-level calls of amplifications 
or deletions across all the genes in each of the samples. The Poisson distribution plot was 
generated with rate estimated by mean number of alterations, i.e., total number of 
alterations across all genes divided by the number of genes.  
GSEA was used investigate the functional significance of population frequency of 
gene-level alterations (Subramanian et al., 2005). We ordered the genes using the CNV 
population frequency as the metric (amplifications and deletions, respectively). To 
construct a functional module map, we performed the preranked version of GSEA using 
the genomic log2 ratios of each gene for individual samples. Among Gene Ontology (GO) 
(Harris et al., 2004) functional categories from MSigDB (c5 category), we selected 133 
functional categories that showed significant enriched (false discovery rate or FDR < 0.05) 
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at least one sample.  The significance of enrichment was converted into matrix value (-
log10 P values) and performed hierarchical clustering.  
To rigorously identify power law behavior, we follow a published statistical 
framework for discerning and quantifying power law behavior (Clauset et al., 2009). The 
procedure available in R is a statistical procedure that combines maximum-likelihood 
fitting methods with goodness-of-it fit test based on the Kolmogorov-Smirnov statistic and 
likelihood ratios. The likelihood ratio test is used to compute the likelihood of the data 
under two competing distributions. The distribution with the higher likelihood is the 
better fit to the data. We compare the Power law distribution to multiple distributions 
including Power law + cutoff, Poisson, lognormal, exponential and Weibull distributions 
at varying thresholds for amplifications and deletions separately. 
 
2.3 Results 
2.3.1. Power law analysis 
The common strategy for identifying power law distributions has been a 
histogram of a quantity that appears as a straight line when plotted on logarithmic scales 
as seen in Figure 2.1 above CBS segmentation log ratio thresholds below -1.0 or above 
1.0. The y-axis represents the number of genes with a given population frequency (x-axis).  
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Figure 2.1: Log-Log Scale Plot of the Distribution of CNVs in GBM. The number of genes above 
the log-ratio thresholds of +/-(0.2, 0.5, 1).  Only segmentations above each threshold are considered, and 
all genes that overlap with the filtered segments are counted. Amplifications are shown in first row; 
deletions are shown below. 
 
The next step was to compare the observed power law behavior with other 
possible distributions including a random and Poisson distribution, shown in Figure 2.2. 
The population frequency was counted for each of 20,229 autosomal genes across 378 
GBMs at increasing thresholds. The y-axis represents the number of genes with a given 
population frequency (x-axis). Permutation was performed by shuffling the gene-level calls 
of amplifications or deletions across all the genes in each of the samples. The frequency 
was also approximated by Poisson distribution with lambda = x/m (x is the total number 
of genomic events in the dataset; m is the number of genes). We observe that the cancer 
CNV population frequencies are different than the permuted and Poisson distributions.  
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Figure 2.2: Best Distribution: Poisson, Power Law, or Random. The population frequency was 
counted for each of 20,229 autosomal genes across 378 (tumor versus normal) GBMs at increasing 
thresholds (Observed). The y-axis represents the number of genes with a given population frequency (x-
axis). Amplifications (1st row) and deletions (2nd row) are computed separately. Permutation was performed 
by shuffling the gene-level calls of amplifications or deletions across all the genes in each of the samples 
(Permuted). The Poisson distribution plot was generated with rate estimated by mean number of alterations 
(total number of alterations across all genes divided by the number of genes). 
 
To more rigorously determine the best distribution to fit the observed data, we use 
a statistical framework specifically for discerning and quantifying power law behavior 
(Clauset et al., 2009). It combines maximum-likelihood fitting methods with goodness-of-
fit tests and likelihood ratios comparing the power-law to other common distributions in 
terms of their goodness of fit. Table 2.1 (amplifications) and Table 2.2 (deletions) presents 
the results fitting the observed CNV frequencies to the power law model compared to 
alternative distributions including Poisson, lognormal, exponential and Weibull 
distributions for amplifications and deletions computed separately. Different thresholds 
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on CNV detection sensitivity yield dramatically different estimates of CNV frequencies in 
the population.  As expected, smaller thresholds yields larger regions detected by the 
segmentation algorithm. The threshold selection also has a profound effect on the 
population level frequencies observed in our study.  For each threshold (on CNV 
detection), we give a p-value for the fit to the power-law model and likelihood ratios for 
the alternatives. Positive values of the log likelihood ratios indicate that the power-law 
model is favored over the alternative. At thresholds of +/- 0.75, the power law 
distribution is favored compared to alternatives, giving us much more confidence than 
visual impressions. 
 
 
Poisson log-normal exponential Weibull 
power law  
+ cutoff 
threshold LR p LR p LR p LR p LR p 
0.25 422412.87 0 -10977.36 0 -7836.37 0 -9152.8 0 -704.5 0 
0.5 58099.96 0 399.75 0 5078.78 0 3445.43 0 -366.58 0 
0.75 8286.86 0 1153.47 0 3486.99 0 4024.9 0 16.42 0.25 
1.0 7350.79 0 1173.3 0 3257.78 0 3554.48 0 161.62 0 
1.25 5810.64 0 818.37 0 2164.97 0 2225.86 0 136.6 0 
1.5 4328.33 0 460.84 0 1236.1 0 1160.21 0 72.92 0 
Table 2.1: Tests of Power Law Behavior (Amplifications). For each threshold, we give a p-value 
for the fit to the power-law model and likelihood ratios for the alternatives. Positive values of the log 
likelihood ratios indicate that the power-law model is favored over the alternative. At thresholds of +0.75, 
the power law distribution is favored. 
 
 
Poisson log-normal exponential Weibull 
power law  
+ cutoff 
threshold LR p LR p LR p LR p LR p 
-0.25 310753.76 0.00 -7460.66 0.00 -3838.52 0.00 -5906.13 0.00 -725.83 0.00 
-0.50 14187.52 0.00 -1381.10 0.00 488.08 0.00 1088.97 0.00 -642.66 0.00 
-0.75 10913.96 0.00 1601.99 0.00 5802.89 0.00 6306.36 0.00 265.02 0.00 
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Table 2.2: Tests of Power Law Behavior (Deletions). For each threshold, we give a p-value for the 
fit to the power-law model and likelihood ratios for the alternatives. Positive values of the log likelihood 
ratios indicate that the power-law model is favored over the alternative. At thresholds of -0.75, the power 
law distribution is favored. 
 
2.3.2. Genes and Pathways Functionally Relevant in GBM 
 To better characterize the genes most prevalent at CNV thresholds (+/-0.75) 
where the power law distribution was favored, we identified the most frequently occurring 
genes for amplifications (Figure 2.3) and deletions (Figure 2.4) separately. The most 
frequently occurring genes observed, including EGFR for amplifications and CDK2NA in 
deletions, are known to be associated with GBM (Brennan et al., 2013; Cancer Genome 
Atlas Network, 2008).  
 
Figure 2.3: Top 10 Deleted Genes. For CNV thresholds below -0.75, the top 10 most frequently 
deleted genes in GBMs are shown. Many of the genes such as CDKN2A and CDKN2B are known to be 
involved in GBM (Cancer Genome Atlas Network, 2008).  
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Figure 2.4: Top 10 Amplified Genes. For CNV thresholds above 0.75, the top 10 most frequently 
amplified genes in GBMs are shown. Many of the genes such as EGFR are known to be involved with GBM 
(Cancer Genome Atlas Network, 2008).  
 
To investigate the functional significance of recurrent amplifications and deletions, 
we performed GSEA analysis based on the population frequency of copy number 
aberrations (see section 2.2). Table 2.3 lists the top-enriched Gene Ontology terms for 
recurrent amplifications and deletions, respectively.  Molecular functions potentially 
related to the development or progression of cancers have been identified such as "Cell 
proliferation" and "Cell cycle" enriched in recurrent amplifications and deletions, 
respectively, as well as "Kinase activity" enriched in both. Pathways such as “Response to 
light stimulus” and “Response to temperature stimulus” appear highly ranked in the list 
due to the high overlap of genes with “Kinase activity” and “Cell proliferation.” 
 
Type Function SIZE ES NES 
Gain RESPONSE_TO_LIGHT_STIMULUS 38 0.8973 1.1989 
Gain CELL_MIGRATION 78 0.8565 1.1709 
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Gain POSITIVE_REGULATION_OF_CELL_PROLIFERATION 119 0.8273 1.1389 
Gain PROTEIN_TYROSINE_KINASE_ACTIVITY 61 0.8396 1.1415 
Gain 
G_PROTEIN_SIGNALING__COUPLED_TO_IP3_SECOND_
MESSENGER__PHOSPHOLIPASE_C_ACTIVATING 35 0.8605 1.1496 
Gain 
TRANSMEMBRANE_RECEPTOR_PROTEIN_KINASE_ACTI
VITY 50 0.8296 1.1216 
Gain RESPONSE_TO_TEMPERATURE_STIMULUS 15 0.9683 1.2331 
Gain PHOSPHOINOSITIDE_MEDIATED_SIGNALING 38 0.8605 1.1528 
Gain 
TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KI
NASE_ACTIVITY 43 0.8411 1.1329 
Gain SKELETAL_DEVELOPMENT 85 0.7937 1.0865 
Loss RECEPTOR_MEDIATED_ENDOCYTOSIS 31 0.9142 1.27 
Loss MEIOTIC_CELL_CYCLE 30 0.8743 1.214 
Loss REGULATION_OF_PHOSPHORYLATION 42 0.8516 1.1987 
Loss CARBOHYDRATE_BINDING 62 0.8039 1.1493 
Loss REGULATION_OF_KINASE_ACTIVITY 132 0.7806 1.134 
Loss REGULATION_OF_PROTEIN_KINASE_ACTIVITY 131 0.7793 1.1319 
Loss REGULATION_OF_TRANSFERASE_ACTIVITY 134 0.7709 1.1204 
Loss CELL_CYCLE_PHASE 146 0.7629 1.1108 
Loss CELL_CYCLE_PROCESS 163 0.7542 1.0987 
Loss CELLULAR_CATABOLIC_PROCESS 182 0.7346 1.0717 
Table 2.3: GSEA Results For Population Level Chromosomal Aberrations 
 
To investigate the concordant functional changes mediated by copy number 
alterations, we constructed a functional module map composed of 133 GO categories.  In 
Figure 2.5, we plotted the results of GSEA analysis for each sample and clustered the 
results, with each row corresponding to a GO category and each column corresponding 
to a sample. Clusters of related GO categories are shown as blocks and key groups are 
highlighted as shown. The functionally concordant genomic deletions were observed for 
'Cell cycle' and 'Chromosome/NFkB signaling/kinase' modules while an amplification 
module of 'Development/cell signaling' was noted.  
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Figure 2.5: A Functional Module Map of Chromosomal Copy Number Alterations in GBM. 
GO categories that showed significant enrichment (FDR < 0.05) by GSEA are selected (n = 133; y-axis).  
The matrix values are -log10Pvalue (P value from preranked GSEA).  Hierarchical clustering was 
performed to groups the GO categories with similar changes (functional modules) and samples.  
 
2.4 Discussion 
We used TCGA GBM copy number profiles derived from tumor vs. matched 
normal genomes genotyped by Affymetrix SNP 6.0 platforms (n = 378).  The use of 
tumor vs. matched (tumor/normal) pairs is necessary to nullify germ-line variations. We 
measured the population frequency of gene-level alterations (n = 20,283) for various 
cutoffs of chromosomal gains and losses. At each cutoff, we counted the number of genes 
that belong to any of the CNV segments whose log2 ratios are above/below the cutoff for 
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amplifications and deletions separately and observed a power law behavior at increasing 
thresholds. The CNV population frequencies did not visually overlap with randomly 
permuted or Poisson distributions. The detection of power laws is complicated by the 
large fluctuations that occur in the tail of the distributions. We applied the most rigorous 
principled set of techniques that allow for the validation and quantification of power laws. 
The procedure combines maximum-likelihood fitting methods with goodness-of-it fit test 
based on the Kolmogorov-Smirnov statistic and likelihood ratios. The likelihood ratio test 
was used to compute the likelihood of the data under two competing distributions. We 
compared the power law distribution to multiple distributions including Power law + 
cutoff, Poisson, lognormal, exponential and Weibull distributions at varying thresholds for 
amplifications and deletions separately. At copy number thresholds (+/-0.75) for multi-
copy amplification and homozygous deletions, we observed power law distribution of 
population frequency of such gene-level alterations. This work represents a significant 
increase in sample size and genomic resolution for identifying power law distributions for 
chromosomal aberrations in cancer. Importantly, our work showing a long tail 
distribution for the frequency of genomic alterations implies that identification of rare 
cancer-related variants will require a very large number of samples. 
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3 Identification of Rare Germline Copy Number Variations 
Overrepresented in Five Human Cancer Types 
Copy number variations (CNVs) are increasingly recognized as significant disease 
susceptibility markers in many complex disorders including cancer. The availability of a 
large number of CNV profiles in both malignant and normal tissues in cancer patients 
presents an opportunity to characterize not only somatic CNVs but also germline CNVs, 
which may confer increased risk for cancer. 
We explored the germline CNVs in five cancer cohorts from the Cancer Genome 
Atlas (TCGA) consisting of 351 brain, 336 breast, 342 colorectal, 370 renal, and 314 
ovarian cancers, genotyped on Affymetrix SNP6.0 arrays. Comparing these to ~3000 
normal controls from another study, our case-control association study revealed 39 
genomic loci (9 brain, 3 breast, 4 colorectal, 11 renal, and 12 ovarian cancers) as potential 
candidates of tumor susceptibility loci. Many of these loci are new and in some cases are 
associated with a substantial increase in disease risk. The majority of the observed loci do 
not overlap with coding sequences; however, several observed genomic loci overlap with 
known cancer genes including RET in brain cancers, ERBB2 in renal cell carcinomas, 
and DCC in ovarian cancers, all of which have not been previously implicated with 
germline changes in cancer.  
This large-scale genome-wide association study for CNVs across multiple cancer 
types identified several novel rare germline CNVs as cancer predisposing genomic loci. 
These loci can potentially serve as clinically useful markers conferring increased cancer 
risk.  
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3.1.1. Introduction  
The major sources of variation in the genomes of individuals include single 
nucleotide polymorphisms (SNPs), small insertion or deletions (indels), and larger-scale 
variations. The latter can be copy number differences (gains or losses of chromosomal 
segments) or copy number-neutral changes (such as inversions or balanced chromosomal 
translocations). Copy number variation (CNV) refers to large-scale (> 1kb) chromosomal 
copy number changes, e.g., amplifications or deletions compared to a reference genome 
(Freeman et al., 2006), although the size distinction is an artificial one defined by the 
limitations of previous CNV detection methods. Genome-wide CNV screening methods 
using high-resolution oligonucleotide-based microarrays as well as high-throughput 
sequencing have accelerated the cataloguing and characterization of large genomic 
variants.  
Initial CNV studies reported a greater than expected variability in genomic CNVs 
in the normal human population, i.e., a significant fraction of individual human genomes 
may be different from each other (Iafrate et al., 2004; Redon et al., 2006; Sebat et al., 
2004). In 2006, the first large-scale population map of CNVs was constructed, estimating 
that up to 12% of the human genome may harbor CNVs (Redon et al., 2006). Recent 
updates from the Database of Genomic Variants (DGV) currently estimates CNVs to 
encompass up to 22% of the human reference genome and is the most prevalent type (by 
size) of genomic variability between individuals (Iafrate et al., 2004). In the early days, the 
focus of genome-wide association studies (GWAS) was to identify disease-associated SNPs. 
However, as the array platforms and the algorithms for inferring CNVs from the same 
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arrays have improved, the more recent studies have identified a number of germline 
CNVs as potential susceptibility loci for a range of diseases including infectious, 
autoimmune, and neuropsychiatric diseases, as well as cancer (Fanciulli, Petretto, & 
Aitman, 2010; Shlien & Malkin, 2009; Wain, Armour, & Tobin, 2009; Zhang, Gu, 
Hurles, & Lupski, 2009). 
Multiple germline CNVs have been reported as factors predisposing individuals 
towards cancer pathogenesis. For example, CNVs at 3p25 and 2p24.3 were associated 
with the aggressiveness of the prostate cancer (Liu et al., 2009; Thean et al., 2010). 
Deletions and rearrangements in the BRCA family of genes have been implicated in breast 
and ovarian cancer (Montagna, 2003; Petrij-Bosch et al., 1997). Deletions of GSTM1 and 
GSTT1 were shown to decrease the 5-year cancer survival rates for bladder and prostate 
cancers in the Dutch general population (Nørskov et al., 2011). A recent large-scale CNV 
association study revealed that CNVs at 1q21.1 involving the NBPF family of genes were 
found to predispose individuals to neuroblastoma (Diskin et al., 2009).  
In this study, we identified recurrent genomic CNVs in cancer patients from the 
Cancer Genome Atlas (TCGA) (Cancer Genome Atlas Network, 2008, 2011, 2012a, 
2012b) that may be associated with increased susceptibility for cancer. For five major 
types of human cancers (breast invasive carcinomas (Cancer Genome Atlas Network, 
2012b), colorectal cancers (Cancer Genome Atlas Network, 2012a), glioblastoma 
multiforme (Cancer Genome Atlas Network, 2008), ovarian serous cystadenocarcinomas 
(Cancer Genome Atlas Network, 2011), and renal cell carcinomas (Cancer Genome Atlas 
Network, 2013)), germline CNV calls from each cancer cohort was compared to a normal 
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control population obtained from an unrelated large GWAS study (Kathiresan et al., 
2009). Our results provide an initial catalog of germline CNVs that are associated with an 
individual’s predisposition to specific cancers and may serve as biomarkers in cancer 
screening. 
 
3.2 Methods 
3.2.1. Sample selection 
Genotyping was performed using the Affymetrix SNP 6.0 platform by TCGA 
consortium. Cases are germline-derived DNA samples (peripheral blood) of European 
ancestry; raw .CEL files were downloaded from The Cancer Genome Atlas Data Portal 
(https://tcga-data.nci.nih.gov) in May 2012. Control samples were obtained from the 
Myocardial Infarction Genetics Consortium (MIGEN) (phs000294.v1.p1) (Kathiresan et 
al., 2009). Raw .CEL files for healthy controls of European ancestry (n=3,074) were 
obtained from the investigators on the project. 
 
3.2.2. CNV detection 
CNVs were called using the PennCNV-Affy6 protocol (2011 Jun16 version) for 
genome build hg18. PennCNV uses a hidden Markov model that incorporates Log R 
Ratio (LRR) values, B Allele Frequency, SNP spacing, and population frequency to 
generate CNV calls for each sample (Wang et al., 2007). Low quality samples were 
eliminated from subsequent analysis using defaults in PennCNVs filter_cnv.pl program in 
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addition to filtering samples with a standard deviation of normalized intensity (LRR) > 
0.35. The LRR is a normalized measure of total signal intensity for two alleles of a SNP. 
 
3.2.3. CNVR detection and association testing 
CNVRuler (v1.3) was used to merge individual CNVs into common CNV regions 
(CNVR) for each cancer and control set (Kim et al., 2012). CNVRs that did not have a 
recurrence of > 0.1 were filtered from the list. CNVR frequencies between each cancer 
set and controls were evaluated using two-tailed Fisher’s exact test. Significant (P < 1.0 x 
10-5) differences were considered as potential associations were subsequently evaluated. 
The overlap with known CNVs was determined by counting the number of times each 
CNVR was observed in the Database of Genomic Variants (DGV) using release 2012-03-
29 (Iafrate et al., 2004). Since CNV boundaries defined by DGV are known to be 
variable and not entirely accurate, we address this shortcoming by classifying CNVRs 
observed in less than a 100 individuals from DGV as a rare event.   
 	  
3.3 Results and discussion  
3.3.1. Study design 
The Cancer Genome Atlas (TCGA) has aimed to identify and catalog major 
cancer-causing genomic changes by profiling 500 patients for each of  >20 cancer types. 
For each patient, DNA from tumor and matched control were profiled, with peripheral 
blood as the control in most cases and a non-tumor tissue in a small subset of cases. With 
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the project near completion, it has provided an access to unprecedented amount of 
genomic profiling data from cancer patients, including exome sequencing for most cases, 
whole-genome sequencing (~10% of cases in many tumor types), RNA and microRNA 
expression, DNA methylation at CpG islands, and DNA copy number. To characterize 
CNVs, every sample was profiled on Affymetrix SNP 6.0 arrays. In the pilot phase of the 
project, the same samples were also profiled on the Illumina and Agilent arrays as well; 
low-pass whole-genome sequencing (6-8X) was also utilized but only for a subset of the 
cases. For this study, we focused on germline copy number profiles generated on the 
Affymetrix SNP 6.0 platform because it allows us to examine the large number of cases as 
well as having the highest probe density (~1 million probes primarily for SNP detection 
and another ~1 million for CNVs). We chose cancer types with at least 400 normal 
samples at the beginning of our study, resulting in a total of 1,779 cases across the five 
cancer types mentioned earlier. The raw data was downloaded from the Cancer Genome 
Atlas data portal (https://tcga-data.nci.nih.gov/tcga/). 
One of the challenges for our analysis was to identify a proper control dataset. 
First, it was important to find a dataset with a sufficient large sample size to detect rare 
variants. Studies from the 1000 Genomes project have found that rare genomic variants 
vastly outnumber common variants (Fanciulli et al., 2010), identifying approximately 
20,000 CNVs with frequencies down to 1% (Abecasis et al., 2010; Mills et al., 2011). 
Without a large enough control set, CNVs identified from TCGA germline samples may 
include rare variants in the population not related to cancer. Second, assessment of CNVs 
can be confounded by differences in array platforms and methods of analysis [23]. Thus it 
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was necessary to that the control subjects were profiled on the same Affymetrix SNP6.0 
platform, using the same analytical parameters. Third, analysis results can also be 
confounded by ethnic backgrounds (Jakobsson et al., 2008; Perry et al., 2008; Pinto et al., 
2011; White et al., 2007). To minimize this effect, we limited our analysis to individuals of 
Western European descent, due to low numbers of samples available for other ethnicities, 
and had to use a control set from a similar population. Finally, we have found that, most 
GWAS studies make genotype data available but not raw data even after publication. For 
the current study, it was necessary to access the raw data to process the entire data 
uniformly. After extensive searching for healthy human controls, we converged on the 
data available from the Myocardial Infarction Genetics Consortium (MIGEN), which 
had over 3,074 healthy controls generated on the Affymetrix SNP 6.0 platform. The data 
was obtained from dbGAP and from the investigators on the project. For this dataset, the 
samples were drawn from six collection sites: Boston, MA; Seattle, WA; Helsinki, Finland; 
Malmö, Sweden; Barcelona, Spain; and Milan, Italy (Kathiresan et al., 2009).  
 
3.3.2. Identification of copy number variable regions 
The overview of the data and analysis steps are shown in Figure 3.1. To identify 
CNVs, we used the PennCNV (Wang et al., 2007) software package. This algorithm 
employs a hidden Markov model to segment the total signal intensity for both alleles (log 
R ratio, or LRR) and allelic intensity ratio between the two alleles (B allele frequency, or 
BAF) for each probe across the genome. Additional sources of information such as probe 
spacing and population allele frequency are incorporated.  
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Figure 3.1: Workflow for our CNV analysis. The number of samples at various steps are indicated.  
 
Across all five cancers, we identified 88,910 CNVs from 1,779 patients with a 
median CNV count of 15 gains and 32 losses per patient. The median length of these 
CNVs was 53.79kb and 17.34kb for gains and losses, respectively. For our control 
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population, we included 3,074 Western European patients producing a total of 161,910 
CNVs, which had a median CNV count of 18 gains and 34 losses per sample. As 
expected, the control population had a comparable CNV frequency to the germline DNA 
in cancer cases. Summaries of the dataset and characteristics are described in Table 3.1. 
 
Type 
Total 
Samples 
bFiltered 
Samples 
Total 
CNVs 
Average 
CNV size 
(bp) 
Median CNVs 
per sample 
Breast (BRCA) 555 336 15836 105943.46 46 
Brain (GBM) 524 351 18072 111177.71 45 
Colon (COAD) 444 342 17830 93776.88 49 
Kidney (KIRC) 505 370 17968 99424.12 47 
Ovarian (OV) 514 380 19204 95492.29 47 
Control (MIGEN) 3074 2956 161910 79388.82 52 
Table 3.1: Characterization of CNVs For Each Cancer and Control Sets. aMarks sets.. bSamples 
that did not pass quality control metrics and were not of Western European descent were removed from 
subsequent analysis.  
 
We used CNVruler (Kim et al., 2012) to merge individual CNVs into common 
CNV regions (CNVR) and identify significant regions associated with risk of individual 
cancers. CNVruler is one of the few tools that integrate multiple methods for calculating 
CNVRs with several statistical association tests and options for population stratification. 
The frequencies of specific CNVRs were compared between each cancer cohort and the 
MIGEN control group using Fisher’s exact test.  To detect potential association, we used 
the significance level of P < 1 × 10-5, following the practice in building a catalog of 
significant results in GWAS studies (http://www.genome.gov/27529028). Given that the 
number of CNVRs is generally smaller than 5000, this threshold on the p-value is more 
conservative than the Bonferroni correction on P = 0.05. Amplified and deleted CNVRs 
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were calculated separately. A total of 75 rare and common CNVRs were significantly 
associated with at least one of the cancers studied.   
To assess the possible phenotypic impact of these CNVRs, we compared them to 
known genomic imbalances collected in the Database of Genomic Variants (DGV) 
(Rodriguez-Revenga, Mila, Rosenberg, Lamb, & Lee, 2007). The DGV released we 
utilized includes 290,000 CNVs from 8802 samples compiled from 53 studies, covering 
66.5% of the human genome (Iafrate et al., 2004). In principle, cancer specific CNVRs 
found in DGV reduces the likelihood of the region being causative. Since DGV is not a 
curated database and integrates data from multiple platforms with significantly varying 
probe coverage and resolutions, many variants are known to have inaccurate boundaries, 
overestimated sizes (Conrad et al., 2010; Perry et al., 2008) and misleading frequencies 
(Kidd, Newman, Tuzun, Kaul, & Eichler, 2007). However, regions identified in many 
studies or independent methods are most likely real. We filtered common CNVRs found 
in multiple studies and samples from DGV and obtained on a total of 39 rare CNVRs 
that are associated with cancer risks for five cancers. The full list of significant germline 
CNVRs is available in Table 3.2. 
 
Cancer Chr. 
Start 
Position 
Size 
(bp) 
Freq. 
(Control)a 
Freq. 
(Case)b Type 
Odds 
Ratio P-valuec Gene(s)d 
BRCA 11 51185363 8472 0% 1.49% Loss - 1.08E-05 
 BRCA 3 62936471 30079 0.07% 1.79% Loss 26.85 2.54E-05 
 BRCA 3 26586501 3489 0.17% 2.08% Loss 12.56 5.47E-05 
 COAD 3 107601890 16832 0.03% 2.34% Loss 70.78 1.02E-07 
 COAD 10 101261779 22068 0% 1.46% Loss - 1.20E-06 NKX2-3 
COAD 4 156797864 71044 0.24% 2.34% Loss 10.09 4.13E-05 GUCY1A3 
COAD 7 29635116 120414 0.03% 1.46% Gain 43.84 6.41E-05 
DPY19L2P3, 
LOC100271874, 
LOC646762 
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GBM 14 21685305 117313 0.30% 5.41% Loss 18.74 5.54E-13 TRA@, TRD 
GBM 5 57361784 7507 16.5% 33.0% Loss 2.50 1.54E-12 
 GBM 22 47288391 152640 0.07% 2.85% Loss 43.31 8.76E-09 FAM19A5 
GBM 7 38257218 88038 0.84% 5.41% Loss 6.71 2.25E-08 TARP 
GBM 5 10927644 15240 0% 1.99% Loss - 1.44E-07 
 GBM 14 21804698 2132 0.10% 2.28% Loss 22.96 1.85E-06 TRA@, TRD 
GBM 14 21681152 2379 0.20% 2.56% Loss 12.94 4.34E-06 TRA@, TRD 
GBM 10 42882051 56351 0.30% 2.56% Loss 8.62 3.15E-05 RET 
GBM 7 61793773 26492 1.56% 5.13% Loss 3.42 6.89E-05 
 KIRC 14 21681152 2379 0.20% 5.41% Loss 28.10 6.44E-15 TRA@, TRD 
KIRC 10 96855083 4614 0.07% 3.24% Loss 49.51 2.26E-10 
 KIRC 3 89250592 142689 0% 1.62% Gain - 1.83E-06 EPHA3 
KIRC 2 97429511 99111 2.17% 7.03% Loss 3.42 2.33E-06 ANKRD36B 
KIRC 6 118470482 5095 0.24% 2.43% Loss 10.50 1.33E-05 SLC35F1 
KIRC 17 34990311 173216 0.64% 3.51% Gain 5.63 1.56E-05 
C17orf37, 
ERBB2, GRB7, 
NEUROD2, 
PGAP3, PNMT, 
PPP1R1B, 
STARD3, TCAP 
KIRC 4 103363913 68353 0.10% 1.89% Loss 18.99 1.78E-05 SLC39A8 
KIRC 2 91049141 1293 0.58% 3.24% Loss 5.79 2.68E-05 
 
KIRC 4 2281 109282 3.45% 8.38% Gain 2.56 5.16E-05 
ZNF595, 
ZNF718 
KIRC 7 19542080 79082 0.04% 1.35% Loss 40.48 9.06E-05 
 KIRC 12 130123182 31743 0.04% 1.35% Loss 40.48 9.06E-05 GPR133 
OV 13 54589383 6308 0.07% 2.37% Loss 35.83 1.32E-07 
 OV 4 36584413 19612 0.03% 2.11% Loss 63.55 2.15E-07 
 OV 1 244904225 32016 0% 1.84% Gain - 2.37E-07 
 OV 10 66977929 15004 4.57% 11.6% Gain 2.74 3.29E-07 
 OV 2 192993 16566 0% 1.58% Gain - 2.11E-06 SH3YL1 
OV 1 229982231 47730 0% 1.58% Gain - 2.11E-06 
DISC1, DISC2, 
TSNAX-DISC1 
OV 2 7529134 41988 0% 1.58% Gain - 2.11E-06 
 OV 10 495985 75956 0% 1.32% Gain - 1.87E-05 DIP2C 
OV 5 174076632 49822 0% 1.32% Gain - 1.87E-05 MSX2 
OV 18 48381779 37120 0% 1.32% Gain - 1.87E-05 DCC 
OV 18 45329306 46009 0% 1.32% Gain - 1.87E-05 LIPG 
OV 4 172611459 3050 4.63% 10.0% Loss 2.29 6.75E-05   
Table 3.2: Significant Cancer Germline Copy Number Variable Regions. Genomic coordinates 
are based on UCSC human genome build hg18. aGermline cancer samples were downloaded from the 
Cancer Genome Atlas (https://tcga-data.nci.nih.gov/tcga/). bControls are based on 2,956 healthy human 
samples provided by the Myocardial Infarction Genetics Consortium. cThe P-value is based on two-tailed 
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Fisher's exact test comparing gain and loss frequency in cases versus controls using a threshold of 10-5. 
dOverlapping genes with CNVRs were determined using Refseq as the annotation source.  
 
There are over 200 inherited cancer syndromes that account for 5-10% of all 
cancer cases (Nagy, Sweet, & Eng, 2004). However all known cancer susceptibility genes 
account for only 1% to 15% of familial cancers (Nortier, Martinez, & Schmeiser, 2000). 
Therefore, a large fraction of variants that increase genetic predisposition in hereditary 
cancers remains to be uncovered. Common CNVRs are unlikely to be associated with 
disease (Craddock et al., 2010), but highly penetrant rare CNVRs are likely to increase 
cancer susceptibility (Conrad et al., 2010).  With our larger sample size compared to 
previous case-control association studies, we have greater statistical power to identify 
novel germline CNVRs associated with cancer.  
 
3.3.3. Breast invasive carcinoma 
Breast cancer is the most common female malignancy in the world, with greater 
than 1.3 million cases and over 450,000 deaths each year (Cancer., 2008). One in eight 
women in the United States will be diagnosed with breast cancer and accounts for 30% of 
all female cancers (Siegel, Naishadham, & Jemal, 2012). It is a complex genetic disease 
where up to a quarter of all cases are likely to be hereditary (Nortier et al., 2000). 
Genomic gains and losses in BRCA1/BRCA2 have been reported to increase 
predisposition for hereditary breast and ovarian cancers (Bunyan et al., 2004; Montagna, 
2003; Petrij-Bosch et al., 1997). CNVs at 17q11.2, 11q13.1, and 6q24.1 were recently 
reported to be strongly associated with breast cancer recurrence (Sapkota et al., 2013). 
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Inheritable syndromes including Li-Fraumeni syndrome (LFS) and Peutz-Jeghers 
syndrome (PJS) have genomic rearrangements in TP53 and STK11, respectively, that 
increase risk of early onset cancers including breast (Bougeard et al., 2003; Le Meur et al., 
2004). Clinically relevant mutations in BRCA1, BRCA2, TP53, and PTEN are currently 
recognized and account for 5-10% of all new cases leaving a large fraction of genetic 
predisposition to be uncovered (Kenemans, Verstraeten, & Verheijen, 2004). 
Our analysis of germline CNVs for 336 breast cancer patients revealed 10,408 
CNVs as losses and 5,428 as gains (median count of 15 gains and 31 losses per individual). 
We found three CNVR losses significantly enriched in the germline of breast cancer 
patients in 11p11.12, 3p14.2, and 3p24.1. The deletion at 11p11.12 was detected in five 
breast cancer patients (the length of CNVR is 8kb) but not observed in the control set (P 
= 1.08 x 10-5). The deletion at 3p14.2 (30kb in length) was observed in 1.8% (6/336) of 
cases and 0.07% (2/2956) in the control population (P = 2.54 x 10-5, odds ratio (OR) = 
26.85). The deletion at 3p24.1 was 3kb in length and observed in 2.1% (7/336) of the 
cases and 0.16% (5/2956) in the controls (P = 5.47 x 10-5, OR = 12.57). None of these 
deletions showed overlap with known coding sequences. 
 
3.3.4. Colorectal cancers 
Colon cancer is the fourth most commonly diagnosed malignancy and the second 
leading cause of cancer-related mortality worldwide with a 6% lifetime risk in the United 
States (Siegel et al., 2012).  The present estimate is that 15–30% of cases may have a 
major hereditary component, given a family history of the disease (Kerber, Neklason, 
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Samowitz, & Burt, 2005; Taylor, Burt, Williams, Haug, & Cannon-Albright, 2010). 
CNVRs associated with colon cancer have been found in multiple inherited colorectal 
tumor syndromes. Large deletions in APC have increased risk for patients with familial 
adenomatous polyposis coli (FAP) (Michils et al., 2005). A CNVR at 3p26 is associated 
with APC mutation negative familial colorectal cancer (Thean et al., 2010). Hereditary 
non-polyposis colorectal cancer (HNPCC or Lynch syndrome) accounts for 5% of colon 
cancers with predisposing CNV deletions in PMS2, MLH1, MSH2, and MSH6 (Bunyan et 
al., 2004; Nyström-Lahti et al., 1995; Overbeek et al., 2007; Plaschke, 2003; Wijnen et al., 
1998). Genomic rearrangements in STK11 increase risk of early onset cancers including 
colon in patients with Peutz-Jeghers syndrome (PJS) (Le Meur et al., 2004). 
We identified 12,031 CNVs as losses and 5,799 as gains from 342 genomes of 
colon cancer patients (median count of 15 gains and 34 losses per individual). Four 
significant regions associated with colon cancer were identified at 3q13.11, 10q24.2, and 
4q32.1 as losses with a gain at 7p15.1. The most significant deletion of 3q13.11 was 16kb 
in length and did not overlap with any coding sequences. It was observed in 2.3% (8/342) 
of cases and 0.03% (7/2956) of controls (P = 1.02 x 10-7, OR = 70.78). The 10q24.2 
deletion was 22kb in size and occurred in 1.75% (6/342) of cases, not observed in the 
control set (P = 1.2 x 10-7). The loss involving the first exon and 5' untranslated regions 
(UTR) of NKX2-3 was observed for four patients (Figure 3.2A). NKX2-3 encodes a 
homeodomain containing transcription factors. Its variants have been previously reported 
to be associated with inflammatory bowel diseases, the premalignant disorder of 
colorectal cancers (Franke et al., 2008; Wellcome, Case, & Consortium, 2007). The 
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deletion at 4q32.1 involving GUCY1A3 was also observed in eight colorectal cancer 
patients (P = 4.13 x 10-5, OR = 10.09). Large CNVs (~120kb) encompassing several 
genes of DPY19L2P3, LOC100271874, LOC646762 were observed in five colorectal 
patients (1.46%) and was only observed in the control set once (P = 6.41 x 10-5, OR = 
43.84).  
 
3.3.5. Glioblastoma multiforme 
Glioblastoma multiforme (GBM) is the most deadly subtype of brain tumors in 
adults. In 2012, 22,910 Americans were estimated to have been diagnosed and 13,700 
were estimated to have died from brain and other nervous cancers (Siegel et al., 2012). 
Despite being relatively uncommon, GBMs are incurable and are responsible for a 
disproportionately share of cancer mortality where patients typically survive less than 18 
months (Meyer, 2008). Approximately 5% of patients have a family history including rare 
genetic syndromes including Li-Fraumeni syndrome where genomic rearrangements in 
TP53 were associated with elevated brain cancer risk (Bougeard et al., 2003). Germline 
duplications in SMARCB1 are associated with increased risk of malignant rhabdoid 
tumors (MRT) found in the brain (Swensen et al., 2009). It has also been suggested that 
hemizygous germline deletions of 22q are a possible predisposition loci for GBM (Díaz de 
Ståhl et al., 2005). 
We identified 12,875 CNVs as losses and 5,197 as gains (median count of 13 gains 
and 32 losses per individual) from 351 genomes of GBM patients. A total of nine 
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significant CNVRs associated with brain malignancies were observed. All associations 
were identified as genomic losses. Four deletions (one at 7p14.1 and three at 14q11.2) 
overlapped with genomic loci encoding T cell receptors (TCR) including the most 
significant involving TCR-alpha that occurred in 5.4% (19/351) of cases 0.3% (9/2956) of 
controls (P = 5.54 x 10-12, OR = 18.74). These deletions overlap with known regions 
associated with less aggressive forms of neuroblastoma (Diskin et al., 2009). The deletions 
at 5q11.2 were recurrent in case (33%; 116/351) and control populations (16.5%; 
487/2956) (P = 1.54 x 10-12, OR = 2.5), but did not involve known coding regions. The 
deletion observed at 22q13.32 overlaps with FAM19A5, the association of which was 
previously observed with pancreatic cancers (Wu et al., 2012). This deletion was observed 
in 2.8% (10/351) of cases and 0.07% (2/2956) of controls (P = 8.76 x 10-9, OR = 43.31). 
Other deletions associated with GBM (~15 kb at 5p14.2 and ~26kb at 7q11.21) did not 
involve coding regions. The association of deletions involving the RET proto-oncogene 
with GBM was observed. The deletions occurred in 2.6% (9/351) of cases and 0.3% 
(9/2956) of the controls (P = 3.15 x 10-5, OR = 8.62) (Figure 3.2B). RET encodes a 
receptor tyrosine kinase that plays an important role in neural development (Manié, 
Santoro, Fusco, & Billaud, 2001) known to be implicated with neuroblastoma (Bunone et 
al., 1995) and thyroid cancers (“Molecular biology of the MEN2 gene,” 1998).  
 
3.3.6. Renal clear cell carcinoma 
Renal clear cell carcinoma is the most common type of kidney cancer, which 
accounts for 3-5% of all adult malignancies (Siegel et al., 2012). It is the sixth most 
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common in cancer in men and eighth most common in woman. Approximately 2-3% of 
cases are hereditary including several autosomal dominant syndromes (Maher, 1996). 
Germline deletions in VHL are associated with Von Hippel-Lindau (VHL) disease, which 
is characterized by the development of multiple vascular tumors including the kidney 
(Richards et al., 1993). Rare full gene deletions of FH predispose individuals to hereditary 
leiomyomatosis and renal cell cancer (HLRCC) (Ahvenainen et al., 2008). Children with 
malignant rhabhoid tumors (MRT), a particularly aggressive pediatric kidney cancer, 
have found germline duplications in SMARCB1 associated with increased cancer risk 
(Swensen et al., 2009). Large genomic deletions and rearrangements in TSC1 and TSC2 
in tuberous sclerosis contribute to harmartomas found in multiple organs including the 
kidney (Kozlowski et al., 2007). 
We identified 12,242 CNVs as losses and 5,726 as gains (median count of 15 gains 
and 32 losses per individual) from 370 genomes of renal cell carcinoma (clear type). Nine 
significant CNVRs were associated with kidney cancer including six loss CNVRs, and 
three gain CNVRs. The most significant CNVR occurred as a deletion at 14q11.2 
involving genomic loci encoding TCR-alpha (P = 6.44 x 10-15, OR = 28.09). The second 
significant locus was observed at 10q23.33 (P = 2.26 x 10-10, OR = 49.50) without 
involving coding sequences. Some of the significant loss CNVRs did involve coding 
sequences. For example, deletions involving ANKRD36B were observed in 2q11.2 
occurred in 7.0% (26/370) of cases and 2.16% (64/2956) of controls (P = 2.33 x 10-6, OR 
= 3.41). Deletions involving solute carrier family-coding regions were observed at two 
genomic loci; 6q22.2 (SLC35F1; P = 1.33 x 10-5, OR = 10.5) and 4q24 (SLC39A8; P = 
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1.78 x 10-5, OR = 18.98), respectively. Five patients showed deletions involving the 
genetic locus encoding G protein-coupled receptor 133 (GPR133), but for only one 
control individual (P = 9.06 x 10-5, OR = 40.48). The remaining CNVRs observed at 
2p11.1 and 7p15.3 (observed in 3.2% and 1.4% of cases, respectively) did not overlap 
with any genes. The gains at 3p11.2, 17q12, and 4p16.3 were significantly enriched in 
kidney cancer patients. A CNVR in 3p11.2 encompassing EPHA3 was observed for six 
cancer patients (1.6%) and was not found in the control population (P = 1.83 x 10-6). A 
large gain (~173kb) at 17q12 overlaps with multiple cancer-related genes including 
C17orf37, ERBB2, GRB7, NEUROD2, PGAP3, PNMT, PPP1R1B, STARD3, and TCAP (P 
= 1.56 x 10-5, OR = 5.62). All 13 germline gains observed in the cancer patients 
encompass the majority of ERBB2-coding loci (Figure 3.2C) often extending GRB7-
encoding locus. The biological implication of germline amplification involving ERBB2 is 
not well understood. However, the known roles of somatic amplification in certain tumor 
types such as breast cancer raises a hypothesis that different germline copy numbers of 
ERBB2 may be a predisposing factor in the affected individuals, which requires further 
investigation. The other gain of 109kb occurring in 4p16.3 overlapping with ZNF595 and 
ZNF718 occurred 8.4% (31/370) of cases and 3.4% (102/2956) of controls (P = 5.16 x 10-
5, OR = 2.56).  	  
3.3.7. Ovarian serous cystadenocarcinoma  
Ovarian cancer is the fourth most frequent cancer in woman worldwide. In the 
United States, approximately 22,910 women will be newly diagnosed resulting in 15,500 
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deaths per year (Siegel et al., 2012). At least 10% of ovarian tumors are hereditary and 
associated with autosomal dominant syndromes (Russo et al., 2009). Rare hereditary 
syndromes including Peutz-Jeghers syndrome (PJS) and Gorlin syndrome have germline 
deletions in STK11 and Patch genes, respectively, that increase the risk of early onset 
ovarian cancer (Le Meur et al., 2004; Shimkets et al., 1996). Germline copy number 
variants in BRCA1 and BRCA2 are known to increase risk of hereditary breast/ovarian 
cancers independent of their BRCA1/BRCA2 mutation status (Bunyan et al., 2004; 
Krepischi et al., 2012).  
Our analysis revealed a total of 12,612 CNVs as losses and 6,592 as gains in 380 
ovarian cancer patients (median count of 15 gains and 32 losses per individual). A total of 
12 genomic loci showed significant association with ovarian cancer, nine of which were 
gains and three as losses. Six of the 12 genomic loci were observed in coding regions. Two 
gain CNVRs including a 16kb segment in genomic loci encoding SH3YL1 (2p25.3) and a 
47kb region overlapping with DISC1, DISC2, and TSNAX-DISC1 (1q42.2) were both 
observed at the same frequency of 1.6% (6/380) but not observed in the controls (P = 
2.11 x 10-6). Genomic loci encoding DIP2C (chr10), MSX2 (chr5), DCC (chr18), and LIPG 
(chr18) also showed similar frequencies in the ovarian cancer patients of 1.3% (5/380) but 
not in the control (P = 1.87 x 10-5). Among them, the association with MSX2 and ovarian 
cancer pathogenesis has been previously reported and DCC (Zhai et al., 2011), where the 
loss of expression was observed in ovarian cancer (Meimei et al., 2011) (Figure 3.2D).  
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Figure 3.2: Illustrative examples of rare germline CNVRs over-represented in specific 
cancers. In each plot, the first two tracks after the genomic coordinates show the RefSeq gene annotations 
and the positions of the probles on the Affymetrix SNP6.0 arrays. Below that, germline CNVs for cancers 
cases are indicated in blue (losses) and red (gains), followed by CNVs observed in control individuals in 
black. (a) 22kb loss affecting NKX2-3 in 6 colorectal cancer cases (n=342); none is present is the controls 
(n=2956). (b) 56kb loss affecting RET in 9 glioblastoma patients; 9 CNVs are also found in the controls but 
the sample size of the control set is almost 10-fold greater (351 vs 2956), making this statistically significant. 
(c) 173kb gain affecting ERBB2 in 13 kidney cancer cases (n=370); 19 are present in the controls. (d) 37kb 
gain affecting DCC in five ovarian cancer cases (n=380); none are present in the controls. 	  
3.4 Conclusion 
Our study provided a new catalog of over-represented germline CNVs potentially 
contributing to cancer risk in a large population of cancer patients across multiple cancer 
types. As expected, most candidate prognostic CNVs we find have low frequencies, 
despite their statistical significance. Among the most interesting cases are the rare 
germline CNVs affecting RET in GBMs, ERBB2 in renal cell carcinomas, and DCC in 
ovarian cancers. These CNVs may explain some of the disease heritability not accounted 
for by SNPs. Interestingly, no CNVs significantly associated with disease risk are shared 
among cancers, suggesting that either there is a diversity of pathways through which 
germline CNVs confer cancer risks or our sample size is too small to detect such low 
frequency events. Further studies profiling other germline characteristics, such as 
epigenetic alterations and combined effects of multiple variants, will be needed for a more 
comprehensive understanding of cancer predisposition. 
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4 Visualizing Large-Scale Sequencing Studies 
4.1 Introduction 
Visualization is any technique used to create images, diagrams, or animations that 
facilitate insights by replacing arduous cognitive assessment with simple perceptual 
inferences. Graphical representations have widely been used to understand biological 
systems such as metabolism (Michal & Schomburg, 2013), cell signaling (Nishizuka, 1984), 
gene expression (Levine & Davidson, 2005), and the structure of chromatin (Anders, 
2009). With the onslaught of data generated from projects such as the TCGA and 
ENCODE, effective visualizations of genomic variation is increasingly required to gain 
insights into the genetic basis of human health and disease.  
“The purpose of information visualization is to amplify cognitive performance, 
not just to create interesting pictures. Information visualizations should do for the mind 
what automobiles do for the feet.” - Stuart Card (Technologies & Applications, 2008). 
The human visual system has evolved to be highly effective at perceiving certain patterns 
but is quickly overwhelmed when attempting to process large amounts of numerical or 
text data. Presenting information in a concise and consumable manner is a key challenge 
in helping investigators process and derive meaning from the variety and volume of data 
available. Economist Herbert Simon once said, “A wealth of information creates a 
poverty of attention and a need to allocate that attention efficiently among the 
overabundance of information sources that might consume it (Greenberger, 1971).”  
In order to help investigators process and synthesize meaning from the variety and 
volume of data, I applied several visualization techniques and created novel tools for the 
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TCGA and ENCODE projects. The applied interaction techniques for visual data 
exploration follow Shneiderman’s well-known visual information seeking mantra, 
“Overview first, zoom and filter, then details-on-demand (Shneiderman, 1996).”  Seqeyes 
combines linear and circular genomic views to explore and interpret structural variation 
predictions to help guide experimental validation. The modEncode epigenetic browser 
visualizes chromatin organization by applying Hilbert curves and integrating multiple 
data types for a multitude of histone marks and chromatin proteins. Enabling 
investigators to interpret the data without learning sophisticated methods, these results 
present useful strategies for identifying oncogenic variants and visualization tools for 
exploring the variety and volume of data available to big data bioinformatics projects.   
 
4.2 Review of Visualizations in Bioinformatics 
The following sections give a brief overview of common visualization techniques 
used in biology and a discussion of the advantages and disadvantages of commonly used 
visualization techniques including sequence logos, scatter plots, profile plots and heat 
maps, circular plots, networks and how each are used. 
 
4.2.1. Sequence Logos 
Sequence logos are common graphical representations for displaying patterns in 
sequence conservation that was popularized in the early 1990s (Schneider & Stephens, 
1990; Shaner, Blair, & Schneider, 1993). The height of each letter represents the relative 
frequency of variants for each position in a sequence. The overall height at each position 
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indicates the overall sequence conversation measured. As shown in Figure 4.1, sequence 
logos commonly show nucleotide patterns in DNA binding site motifs (Robison, McGuire, 
& Church, 1998) and splice sites (Stephens & Schneider, 1992), while protein logos are 
often used to show amino acid conservation patterns that are structurally and functionally 
important (Galperin, Nikolskaya, & Koonin, 2001; Rigden, Jedrzejas, & Galperin, 2003). 
A tag cloud, popularized by social media, is a similar visualization of text where attributes 
such as size, weight, and color are used to represent each word’s frequency (Hassan-
Montero & Herrero-Solana, 2006). It represents a weighted visual list that helps users 
locate words alphabetically and quickly identify the most common patterns similarly to 
sequence logos. 
 
 
Figure 4.1: Splice Site Sequence Logo. Frequency of nucleotide patterns for Human intron-exon 
splice boundaries. (Source: http://weblogo.berkeley.edu/examples.html) 
 
4.2.2. Scatter Plots 
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Scatter plots use the horizontal axis and vertical axis to plot data. Typically for a 
large body of data, scatter plots visualize how much one variable is affected by a second 
variable. The stronger the relationship the closer the data comes to making a straight line. 
However, this is the plot that is most associated with the maxim, “Correlation does not 
imply causality.” In bioinformatics, MA-plots shown in Figure 4.2 (Bolstad, Irizarry, 
Astrand, & Speed, 2003) are a common tool used for analyzing gene expression data. 
Also known as the Bland-Altman plot (Bland & Altman, 1986), the plot illuminates the 
differences between two variables plotted on the vertical axis against the averages of the 
two variables on the horizontal axis. In genomics, M is the log ratio intensity (i.e. the ratio 
of a gene being expressed in cancer versus a healthy individual) and the A is the average 
expression of that gene in both conditions. It provides a quick view of the distribution of 
data and can help determine if further data normalization is needed. When used in 
concert with dimensionality reduction methods, scatter plots provide insights into the 
overall structure of large multidimensional data sets. Popular methods for dimensionality 
reduction include Principal Component Analysis (Hotelling, 1933) and Multi-
Dimensional Scaling (Kruskal, 1964). 
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Figure 4.2: M Versus A Plot. Example spike-in gene expression data where M represents the gene being 
up or down regulated compared to A, the average intensity across both conditions (Bolstad et al., 2003). 
 
4.2.3. Profile Plots 
Perhaps the most common genomic visualization, a profile plot uses the linear 
genome coordinate along the x-axis and a data value range on the y-axis. Genomic 
coordinates are the driving method for organizing and displaying genomic data. As the 
standard tool for exploring genomes, genome browsers are interactive programs that can 
search through and display genomic data and annotations at various resolutions. Profile 
plots can represent many data types including gene expression, genotype variation, and 
sequence conservation, which can be displayed as separate tracks stacked vertically. 
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Beginning tools displayed early draft assemblies of the original model organism systems 
targeted by the NIH’s Human Genome Project in 1990. AceDB was one of the first 
genome browsers developed for the Caenorhabditis elegans genome (Eeckman & Durbint, 
1995), with GBrowse applied to many of the later model organisms (Stein et al., 2002). 
Other prominent examples include the Ensembl Genome Browser (Stalker et al., 2004) 
and NCBI Map viewer (Wheeler et al., 2000).  
The two most commonly used genome browsers are the UCSC genome browser, 
shown in Figure 4.3, and IGV (Thorvaldsdóttir, Robinson, & Mesirov, 2013) both allow 
for cross-platform access and the ability to customize the data and display representations. 
The UCSC genome browser’s role as a data repository for genomic annotations and its 
development of BigBed and BigWig file formats capable of handling data sets gigabytes in 
size have contributed to its success (Kent et al., 2002). IGV has been developed as a high 
performance viewer capable of integrating clinical data with next generation sequencing 
data.  It provides a tiled data format (TDF) that pre-computes summarizations of 
genomic data at various resolutions providing the quickest response when browsing 
through genomes. A significant disadvantage of this view is that there is limited number of 
tracks that can be viewed effectively at the same time.  
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Figure 4.3: Profile Plots and Heat Maps in GBM. (a) The UCSC Genome Browser displays diverse 
data types across the human genome such as genes where exons are shown as boxers and introns as thin 
lines. ChIP data represented as profile plots. (b) The UCSC Cancer Genomics Browser displays the same 
data as a heat map where deletions are shown in blue and insertions in red. Two publicly available clinical 
parameters are displayed: tumor (olive) versus unaffected (yellow), and male (yellow) versus female (black); 
gray (C. B. Nielsen, Cantor, Dubchak, Gordon, & Wang, 2010). 
 
4.2.4. Heatmaps 
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Heatmaps are graphics that visualize values of a matrix as a shade of color. The 
term “Heatmap” was popularized in 1991 to graphically show real time financial market 
data (patent citation). The idea was borrowed from chloropleth maps, which maps a 
statistical variable such as population density as a color to reveal levels of variability 
within a geographic region (Friendly, 2009). In bioinformatics, Michael Eisen in 1998 
popularized its use and accompanying hierarchical clustering analysis for gene 
microarrays (Eisen, Spellman, Brown, & Botstein, 1998). Figure 4.3b shows how the 
UCSC Cancer Genomics Browser displays gene expression for individuals or sets of 
samples as heatmaps across various clinical features (Zhu et al., 2009). Screen space is the 
limiting factor for the number of profiles being displayed in heatmaps. 
Reordering of rows and columns allowing similar profiles to be near each other 
was first introduced in 1957 (Sneath, 1957).  Dendrograms showing the hierarchy of 
clustering placed adjacent to the heatmaps originated in 1973 (Ling, 1973).  The 
integration of clustering and dendrograms allow investigators to see groups of similarly 
behaving genes, quickly identify outliers, and visualize hundreds of genes as shown in 
Figure 4.3.  
 
4.2.5. Circular Plots 
Displaying data using a circular layout is an effective and scalable method for 
emphasizing relationships between genomic positions such as gene fusion events or 
chromosomal translocations in cancer. The most prominent example, Circos, uses 
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ribbons to encode the position, size, and orientation of the relationship between genomic 
elements (Krzywinski et al., 2009). Circular plots can show a great deal of information in 
a small area and are useful in generating a global view of the data, but can become 
problematic when visualizing multiple rings and zooming. Initially, circular ideograms 
were used to graphically represent the circular structure of microbial genomes (Gibson & 
Smith, 2003; Sato & Ehira, 2003). Relationships between genomic positions were 
typically viewed in a linear layout with connected lines (Dicks, 2000; Kozik, Kochetkova, 
& Michelmore, 2002), however as the number of relationships increased the underlying 
patterns became difficult to discern. Circular maps were adapted from established text 
visualizations that mapped relationships between concepts (Zytkow & Rauch, 1999). 
Benefits of adopting a circular layout for structural variants were first suggested by Ekdahl 
(Ekdahl & Sonnhammer, 2004) and its initial application to cancer was used to display 
end-sequence profiling and finger print profiling of multiple cancer genomes (Volik et al., 
2003).  
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Figure 4.4: Representative Circos Plots. Chromosome rearrangements and gene duplications are 
shown for two tumors from whole genome sequence data. The outer rings signify chromosomes arranged 
end to end. The inner ring shows interchromosomal translocations in purple and copy number data in 
green (Wong, 2012).  
 
4.2.6. Network Visualizations 
Network visualizations are a method of representing the complex interactions that 
occur between biological molecules such as DNA, proteins, and small molecules. With the 
ease of high throughput technologies, there are currently over 500 published biological 
pathway and molecular interaction resources that document millions of types interactions 
(Bader, Cary, & Sander, 2006). Pathways defined by literature (Foundation, 2003), 
descriptive ontologies (Ashburner et al., 2000), protein interaction databases (Prasad, 
Kandasamy, & Pandey, 2009), gene expression profiles (Quackenbush, 2001), and small 
molecule metabolite concentrations (Dunn & Ellis, 2005) are some of the available types 
of resources. Network visualizations grew out of the need to automate and explore large 
biological networks and integrate previously established knowledge.  
In mathematics, networks are graphs that are comprised of a set of pairwise 
relationships. Typically represented as a node-link diagram, biological components such 
as proteins are represented as nodes and interactions between them represented as edges 
(Battista, Eades, Tamassia, & Tollis, 1998).  There are a variety of automated network 
layout algorithms that provide different insights into the underlying relationships of the 
data. Circular network layouts can convey the overall connectedness of the network, 
while force directed layouts identifies hubs and clusters of nodes (Eades, 1984). Node-link 
diagrams provide an easy way to identify nearest neighbors and paths through a network, 
	  	  
49 
however they do not scale well, typically forming a hairball as the density increases. 
Popular programs such as Cytoscape and Gephi are used to generate network diagrams 
and interactively explore the data (Shannon et al., 2003; The Gephi Team, 2008). Hive 
plots are another type of network visualization that create network layouts which are 
comparable and reproducible (Krzywinski, Birol, Jones, & Marra, 2012). 
 
 
Figure 4.5: Multiple Layouts for Network Visualizations. Cytoscape generated images of 
Mycoplasma pneumoniae protein interaction network (> 400 proteins). Colors of nodes are tied to functional 
annotations: Blue, RNA polymerase; green, ribosomal subunits; red, elongation factors. (a) Initial force-
directed layout. (b) Filtered network with same layout algorithm. (c) Layout based on annotated protein 
complexes. (d) Collapse of nodes in each protein complex, simplifying the network (Gehlenborg et al., 
2010). 
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4.3 ModENCODE Epigenetic Browser 
The modEncode epigenetic browser was created as a tool for investigators to 
quickly enable and easily share biological insights from the incredible amount and variety 
of available epigenetic data. Here we visualize a genome-wide chromatin landscape for 
Drosophila melanogaster based on eighteen histone modifications, summarized by nine 
prevalent chromatin states. It empowers investigators to navigate the genome while 
viewing multiple perspectives and resolutions of the data. 
 
4.3.1. Introduction 
Chromatin is comprised of DNA and a variety of modified histones and non-
histone proteins, which have an impact on cell differentiation, gene regulation and other 
key cellular processes. The model organism Encyclopedia of DNA Elements 
(modENCODE) project has created a comprehensive map of chromatin components, 
transcription factors, transcripts, small RNAs and origins of replication in Drosophila 
melanogaster and Caenorhabditis elegans (Gerstein et al., 2010; Roy et al., 2010). For over a 
century, Drosophila has been used as a model system to study chromosome structure and 
function, gene regulation, development, and evolution. The availability of high-quality 
euchromatic and heterochromatic sequence assemblies (Hoskins et al., 2007), maturing 
annotation of functional elements, and a vast array of experimental conditions enhance 
the value of epigenomic studies in Drosophila (Clark et al., 2007). Genome-wide profiling 
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of chromatin elements provides a functional context of the underlying DNA sequences 
(Tweedie et al., 2009). Genomic features such as transcription start sites, enhancers, and 
transcription rates have been associated with patterns of post-translational histone 
modifications and non-histone proteins (Elgin, Yaniv, Mendenhall, & Bernstein, 2008; 
Felsenfeld & Groudine, 2003). 
We present a comprehensive picture of the chromatin landscape in a model 
eukaryotic genome. Combinatorial chromatin ‘states’ are defined at different levels of 
organization, from individual regulatory units to the chromosome level, and relate 
individual states to genome functions. Integrative analysis with other data (non-histone 
chromatin proteins, DNase I hypersensitivity, GRO-Seq reads produced by engaged 
polymerase, short/long RNA products) reveals discrete characteristics of chromosomes, 
genes, regulatory elements and other functional domains. Active genes display distinct 
chromatin signatures that are correlated with disparate gene lengths, exon patterns, 
regulatory functions and genomic contexts. This systematic profiling and integrative 
analysis of chromatin signatures provide insights into how genomic elements are 
regulated and is a resource for future investigations into genome structure and function. 
 
4.3.2. Methods and Data 
A wide range of experimental technologies were integrated and generated to 
create a comprehensive view of the chromatin landscape of Drosophila. Two cell lines 
were analyzed including, S2-DRSC (S2) derived from late male embryonic tissues (stages 
16-17) and ML-DmBG3-c2 (BG3) from the central nervous system of the male third 
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instar larvae. Chromatin immunoprecipitation (ChIP)-array data was generated for 21 
histone modifications and 17 chromosomal proteins labeled and hybridized to Affymetrix 
Drosophila Tiling Arrays v2.0 with multiple independent biological replicates for each 
element (Schwartz et al., 2006). DNase I hypersensitivity sites (DHS) sequencing (DNase-
seq) identified 8,616 high-magnitude DHSs in S2 cells and 6,354 in BG3 cells indicating 
accessible areas of the genome (Crawford et al., 2006). Transcription was measured using 
RNA sequencing (RNA-Seq) estimating the RPKM (reads per kilobase of exonic 
sequence per million reads mapped) for each exon (Cherbas et al., 2011). Global run-on 
sequencing (GRO-seq) was generated to estimate the position, amount, orientation of 
transcriptionally engaged RNA polymerases (Core, Waterfall, & Lis, 2008). To identify 
stalled RNA polymerases short RNA data was generated and processed similarly to the 
GRO-Seq data (Kanhere et al., 2010).  Data for other cell lines and animal stages were 
obtained and integrated from the modENCODE project (http://www.modencode.org).  
 
 
4.3.3. Chromatin States 
In order to better characterize the overall chromatin landscape, nine general 
patterns of chromatin were identified using a Hidden Markov Model (HMM) on eighteen 
histone modifications observed in S2 and BG3 cells. The average enrichment level for 
each histone mark was calculated for every two hundred base pair bins across the genome. 
The model associates each genomic location with a particular state (enriched/ not 
enriched) to identify the prevalent combinatorial patterns generating a novel chromatin-
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centric annotation of the genome. Figure 4.6 illustrates the chromatin state patterns 
across the S2 genome. The details of the machine-learning approach are beyond the 
scope of this dissertation and can be found in the paper (Kharchenko et al., 2011).  
 
Figure 4.6: S2 Chromatin State Karyotype. A genome-wide karyotype view of the domains defined 
by the 9-state model in S2 cells. Centromeres are shown as open circles, and dashed lines span gaps in the 
genome assembly (Kharchenko et al., 2011). 
 
4.3.4. Hilbert Curve 
There are considerable display limitations when visualizing many tracks of 
genome position dependent data when using traditional profile plots. Hilbert curves are a 
visualization technique that complements genome browsers by allowing users to view the 
distribution of features for entire chromosomes, while providing access to local details 
(Anders, 2009). Hilbert curves are a type of space filling curves, first described by Peano 
in 1890 (Hilbert & Sauer, 2009), popularized in 1996 to display stock market prices 
(Keim & Kriegel, 1996), and initially applied to bacterial sequence data in 2003 (Foote & 
Thomas, 2003).  
As a type of space filling curve, plotting space is maximized for each chromosome 
by mapping genomic features from a 1-dimensional sequence onto a 2-dimensional grid. 
It is a technique that scales well and can display thousands of elements legibly. Figure 4.6 
illustrates the recursive steps in generating this curve. Hilbert curves have been shown to 
be the best at preserving locality (Gotsman & Lindenbaum, 1996) and useful in 
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discovering biological patterns in ChIP-SEQ data (Anders, 2009). An advantage of space 
filling curves is that they maintain the spatial proximity of nearby elements allowing data 
close together in the 1-dimensional sequence to remain close in the 2-dimensional grid. 
This property ensures data aggregation to be continuous across varying bin sizes and 
samples. Secondly, when data is aggregated the shape of the data is distinct due to the 
path of the Hilbert curve. The distinct paths help investigators identify patterns distinctive 
to certain biological conditions similar to recognizing the outline of a country. However, 
it can be difficult to relate the position on the Hilbert curve back to the original genomic 
position.  
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Figure 4.6: Generating a Hilbert Curve. The first four steps in its creation. Each iteration consists of 
four rotated repetitions of the curve of the previous iteration (Anders, 2009).  
 
4.3.5. Implementation 
The modENCODE epigenetic browser is an Adobe Flash web based visualization 
connected to a Postgresql 9.0 backend database with Postbio genomic extensions. PostBio 
enables extremely fast genomic range queries and use of complex indexes including multi-
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column B-tree, R-tree, and generalized index search trees (GIST) were implemented and 
optimized (Carvalho, 2008). 
The dm4 version of the Drosophila melanogaster genome with Flybase gene 
annotations were used as the genomic coordinate system and gene definition reference. 
Predicted chromatin states from the HMM as well as the chromatin immunoprecipitation 
profiles for 21 histone modifications and 17 chromosomal proteins were included in the 
database for linear genome browser views. Linear karyotypes and Hilbert curves were 
generated from chromatin states for every chromosome in each of the two cell lines. A 
variety of Hilbert curves were also generated for DNase I hypersensitivity sites, replication 
timing, RNA-Seq, TSSs, and GRO-seq data to enable visual comparisons between 
various biological aspects of chromatin organization. The folded views can be browsed 
alongside the linear annotations and other relevant data online: 
http://compbio.med.harvard.edu/flychromatin. 
 
4.3.6. Discussion 
The modEncode epigenetic browser displays chromatin organization by applying 
Hilbert curves and integrates multiple data types for a vast array of histone marks, 
chromatin proteins, and cell lines. Investigators can interpret chromatin states in terms of 
biological significance without the need to learn sophisticated machine learning methods. 
Combinatorial chromatin ‘states’ are defined at different levels of organization, from 
individual regulatory units to the chromosome level, and relate individual states to 
	  	  
57 
genome functions. The chromatin state model associates each genomic location with a 
particular state, generating a chromatin-centric functional annotation of the genome.  
 
Figure 4.7: Hilbert Curve Applied to Chromosome 3L in S2 Cells. A domain of a given 
chromatin state appears as a patch of uniform color of corresponding size. Thin black lines are used to 
separate regions that are distant on the chromosome. The folded view illustrates chromatin organization 
features that are not easily recognized from a linear view: active TSSs (state 1) appear as small specks 
surrounded by elongation (state 2), commonly next to larger regions marked by H3K36me1-driven (state 4) 
(Kharchenko et al., 2011). 
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Further aspects of chromatin organization can be visualized by folding the 
chromosome using a Hilbert curve, which maintains the spatial proximity of nearby 
elements. Local patches of colors reveal the sizes and relative positions of domains 
associated with particular chromatin states as shown in Figure 4.7. Thin black lines are 
used to separate regions that are distant on the chromosome. The folded view visualizes 
chromatin organization features that are not easily identified from a linear view and 
although this curve is optimal for preserving proximity relationships, some distal sites 
appear adjacent along the fold axis. For example, specks of TSS-proximal regions (state 1) 
are typically contained within larger blocks of transcriptional elongation marks (state 2), 
which are in turn encompassed by extensive patches of H3K36me1-enriched domains 
(state 4) and variable-sized blocks of state 3. The clusters of open chromatin dictated by 
these gene-centric patterns separate by extensive silent domains (state 9) and regions of 
Polycomb-mediated repression (state 6).  
The modEncode epigenetic browser was created as a tool for investigators to 
quickly enable and easily share biological insights from the incredible amount and variety 
of available genomic data. In order to convince investigators that predicted chromatin 
states make biological and quantitative sense, we visualize chromatin states and their 
connection to the original data used to generate the chromatin state model. The user 
interface as shown in Figure 4.8 is composed of four main components: (a) On top, a 
linear karyotype of the chromatin state for the entire chromosome is provided to quickly 
identify the current genomic location. (b) The left visualization is a Hilbert curve of the 
chromatin states for the current chromosome enabling insights to global patterns of 
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chromatin. (c) The right visualization can be changed depending on the type of 
experimental data queried. The linear genome browser is a more detailed view including 
tracks displaying the original histone modifications, chromatin state, and associated gene 
annotations. Hilbert curves of DNase I hypersensitivity sites, replication timing, RNA-Seq, 
TSSs, or GRO-seq are also available to provide additional experimental evidence as seen 
in Figure 4.9 and 4.10. (d) The bottom toolbar enables navigation between cell lines and 
chromosomes, the ability to search for a gene or region, and the desired visualization for 
the right panel.  
The current genomic location is represented as a green circle on Hilbert curves 
and green lines for linear visualizations. Clicking on any view instantly updates all other 
views as seen in Figure 4.9 and Figure 4.10 enabling investigators to continuously see 
multiple perspectives and resolutions of the data and navigate quickly through the 
genome. We link the advantages of several visualization techniques to facilitate insights 
with simple perceptual inferences to create a novel tool that enables biological insights 
into the chromatin landscape of a model eukaryotic genome. 
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Figure 4.8: Exploration of Chromatin Profiles. The user interface integrates multiple data types and 
views. The linear karyotype of the current chromosome is shown on top. The left plot shows the Hilbert 
curve of chromatin states of Chromosome 3L in S2 cells. The right profile view shows the zoomed in view 
of the chromatin state, genes, and the profiles of histone modifications.  
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Figure 4.9: Visual Comparison of Chromatin State with Gene Expression. From the same 
genomic location in Figure 4.8, Hilbert curves of the chromatin state enable easy comparison to 
transcription rates measured by RNA sequencing. Active TSSs (state 1) correlate to active rates of 
transcription (shown in green in right panel).  
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Figure 4.10: Visual Comparison of Chromatin State with Replication Timing. From the same 
genomic location in Figure 4.8, Hilbert curves of the chromatin state can be easily compared to replication 
timing determined by short RNA data of stalled RNA polymerases. Active TSSs (state 1) correlate earlier 
replication (Right panel, red denotes early replication).  
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4.4 Seqeyes – Visualizing Structural Variations in Cancer 
Genomic structural variations are known to play an important role in cancer and 
other diseases. Next-generation sequencing is a key technology for the identification of 
such variations, but current data and algorithms yield many false positives and false 
negative predictions. We have created a visualization tool called Seqeyes to explore and 
interpret predicted structural variations to help guide experimental validations. Users can 
sort, filter, and aggregate samples based on clinical attributes, which facilitates the 
association of phenotypes with specific patterns of structural variation. Our tool provides 
a combination of linear and circular representations. Dual genome browser views show 
detail at multiple locations concurrently, while the circular ideogram view provides a 
global summary. Multiple molecular data types including copy number, gene expression, 
and methylation microarrays are integrated as additional genomic tracks. Seqeyes is a 
novel multi-scale visualization that can interactively navigate dozens of genomes down to 
individual sequencing reads within a web browser.  
 
4.4.1. Introduction 
With advances in next-generation sequencing (NGS) technology, rapid 
improvements in speed, quality, and cost are enabling identification of structural 
variations at an unprecedented pace. NGS, in particular paired-end sequencing, provides 
opportunities to discover structural variants that could not be detected on conventional 
microarray-based platforms, such as dosage-invariant chromosomal translocations and 
inversions. Traditional array based methods have difficulty in predicting exact boundaries 
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due to their low coverage of the genome even with the highest density arrays (>1million 
probes), coverage resolution is still limited to 10-20 kb (N. P. Carter, 2007). Structural 
variations are relevant for both in research and clinic. Algorithms make predictions that 
serve as initial hypotheses for experimental validation. But biologists want to see (a) 
supporting information, e.g. in from of reads in the genomic context (b) other supporting 
information, e.g. other data types, or (c) same predictions in other samples. We explore 
these aspects dealing with multiple types of structural variations (SVs) including deletions, 
amplifications, inversions, tandem duplications, interchromsomal, and intrachromosomal 
translocations as shown in Figure 4.11.  
 
 
Figure 4.11: Types of Structural Variations. (a) Deletion. The paired-end read spans the breakpoint 
of a deletion. The mapped distance of the paired-end reads is larger than the insert size. (b) Insertion. The 
paired-end reads spans an insertion and the distance is less than the insert size. (c) Tandem duplication. The 
read pair spans the middle breakpoint of a tandem duplication. The read pair will have correct orientation 
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but with reverse order. (d) Inversion. The read pair encompasses one breakpoint of an inversion and the 
right end is mapped with incorrect orientation. (e) Intra-chromosomal translocation. Two read pairs span 
the two breakpoints of an intra-chromosomal translocation with one pair having a large mapped distance 
and the other having correct orientation but their ordering reversed. (f) Inter-chromosomal translocation. 
The two ends of the pair are mapped to different chromosomes (Xi, Kim, & Park, 2010). 
  
Traditional genome browsers such as the UCSC Genome Browser were not 
designed with paired-end sequencing in mind. As shown in Figure 4.12, common 
approaches to structural variation visualization include Circos (Krzywinski et al., 2009) 
and Gremlin (O’Brien, Ritz, Raphael, & Laidlaw, 2010). Circos displays various types of 
genomic variations based on a circular ideogram layout, while most genome browsers 
display data in a linear view with multiple genomic tracks based on an individual genome. 
Chromosomal translocations are typically drawn as arcs connecting between 
corresponding genomic regions. We provide a combination of circular and linear views 
integrated with data types from multiple platforms of experimental data and improve 
overall performance by leveraging recent open source indexes available from Postgresql 
including multi-column B+, R+ trees, general index search trees. 
Seqeyes is an Adobe Flash web based visualization connected to a Postgresql 9.0 
database using open source genomic extensions provided by PostBio. Database tables are 
heavily pre-indexed using a combination of B+, R+, GIST, and suffix trees. The use of 
advanced indexes has improved query speed and performance up to a 1000 fold in 
certain cases with up to a 500 million reads in a single table. This pre-indexing 
significantly improves fast random retrieval of genomic alignments and reduces the 
memory overhead required by the visualization. 
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Figure 4.12: Visual Representations for Structural Variations. (a,b) Linear (a) Circular (b) 
reference genome layouts with an arc to depict a translocation between two chromosomes (pink and blue). 
(c) Translocation illustrated as reference segments with chromosome colors corresponding to those in a. (d) 
Dot plot indicating positions of identical sequences. (e) Graph of common sequences and their order (C. 
Nielsen & Wong, 2012). 
 
4.4.2. Methods and Data 
Data was obtained from the TCGA. Paired-end DNA sequencing data were 
obtained for 62 primary tumor samples from patients diagnosed with colorectal 
carcinoma. The samples were processed through an Illumina HiSeq at coverage of 3-5X 
with an insert size of 200 bp – 300 bp. Array based data for methylation, copy number 
variation, and gene expression were also obtained for each sample. Methylation data for 
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each sample were provided the Illumina Infinium HumanMethylation27 BeadChip with 
~15k genes. Copy number changes were identified using Affymetrix Genome Wide SNP 
Array 6.0, while mRNA gene expression measurements were provided by the Agilent 
G4502A platform. 
 
4.4.3. Implementation 
NGS raw reads were mapped to the human genome using BWA. Copy number 
variations were calculated using BIC-Seq (Xi et al., 2011) and structural variation 
predictions were produced by CAPS algorithm specifically calling deletions, insertions, 
inversions, and intra- and interchromosomal translocations.  Postgresql 9.0 was used as 
the database backend and Adobe Flash was used to create the browser-based front end. 
PostBio, used in conjunction with Postgresql 9.0 as the backend database for the 
application, enables extremely fast genomic range queries and use of complex indexes 
including multi-column B-tree, R-tree, and generalized index search trees (GIST) were 
created on the tables stored in the database. Other indexes include stree, which is a 
serialized version of suffix tree implementation in MUMmer (Delcher, Salzberg, & 
Phillippy, 2003). As well as fmindex, a compressed suffix array based on the Burrow-
Wheeler transformation allowing for fast exact matching of short sequences (M. Burrows, 
1994). 
 
4.4.4. Discussion 
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Visualization is used to build evidence for or against hypotheses. Seqeyes provides 
an overview of all SV activity for dozens of cancer samples and allows the samples to be 
filtered and ordered based on relevant clinical attributes. We provide details on demand 
including multiple data types and supporting discordant mate pairs for each SV 
prediction. Typical visual representations of the genome include circular and linear views 
with arcs and blocks denoting genomic variations. Circular views are useful for global 
summaries, while linear views are better suited to more detailed genomic windows. Most 
tools choose either a circular or linear view of the genome. We believe that incorporating 
both views at various scales and contexts improves the overall ability of the user to 
interpret the data.  
The user interface as seen in Figure 4.13 displays a global landscape of SVs in 
colorectal carcinoma. The left navigation toolbar enables users to sort, filter, and 
aggregate samples based on clinical phenotypes such as age, sex, tumor stage, and tumor 
subtype and the ability to searches for specific tumors. The global view will automatically 
update to reflect the selected options. Clicking on a tumor will transition the interface into 
a detailed view for a single sample. The detailed view displays a sortable table of SVs 
found in the selected tumor. Each row when clicked will display a pair of linear genome 
browsers displaying tracks for gene definitions, gene expression, copy number variation, 
and methylation data available at each genomic location associated with the selected SV. 
The integration of multiple data types enriches the biological context and ability for an 
investigator to evaluate a SV.  
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Seqeyes is a novel interactive multi-scale visualization, which provides the ability 
to view dozens of genomes down to individual sequencing reads and genomic tracks. The 
tool provides a combination of linked linear and circular genomic views leveraging the 
advantages of each representation and allows users to filter and group samples based on 
clinical attributes. Multiple genome browsers and integration of multiple experimental 
types help biologists evaluate predictions of SV algorithms to improve successful 
experimental validation. Selected as finalist for Illumina iDEA challenge in 2011, a video 
of the submission is available at http://vimeo.com/21322573.  
 
 
Figure 4.13: Global View of Structural Variations in Colorectal Carcinoma. 62 colorectal 
tumors from the TCGA are displayed using a circular genomic view. Each arc represents a structural 
variation categorized by color such as inversions (yellow), interchromosomal translocations (blue), and 
intrachromsomal translocations (purple). Investigators can sort, filter, and aggregate tumors based on 
various clinical variables such as tumor type, stage, sex, and age (shown in left panel).  
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Figure 4.14: Detailed View of Structural Variations of a Single Tumor. When a single tumor is 
selected, the corresponding tables of structural variations are shown. When looking at a single variation, 
multiple linear genome browsers display gene annotations, gene expression, copy number variation, and 
methylation data available at each genomic location. The integration of multiple data types enriches 
investigators biological understanding.  
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